Wu Shengjia, Huang Hsien Wei, Panchal Aditi, Chowdhury Ekram Ahmed, Shah Dhaval K
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, USA.
J Cereb Blood Flow Metab. 2025 May 13:271678X251333536. doi: 10.1177/0271678X251333536.
Antibody therapy has demonstrated great potential for treating central nervous system (CNS) disorders. Since therapeutic efficacy relies on sufficient exposure in specific brain regions, quantitative understanding of antibody distribution within the brain is crucial. Additionally, insights into antibody brain distribution help elucidate how pathological antibodies accumulate during encephalitis. Accordingly, this study investigated the regional distribution of a non-target-binding antibody (trastuzumab) and a brain-target-binding antibody (anti-NMDAR1) following systemic and intra-CNS administration in rats. After systemic administration, both antibodies showed similar distribution across brain regions, with the olfactory bulb exhibiting significantly higher concentrations. Other regions had comparable exposure, with the striatum or hippocampus showing the lowest exposure. Intra-CSF administration resulted in similar distribution patterns but achieved significantly higher concentrations than systemic administration. In contrast, intra-striatal administration led to diverse distribution, with the highest concentrations near the injection site. Calculations based on striatum and interstitial fluid (ISF) concentrations indicated antibody accumulation in the perivascular space after intra-CNS administration. Target binding influenced distribution primarily after intra-CSF administration, where anti-NMDAR1 showed lower ISF concentrations early and reduced CSF concentrations later. These findings provide valuable quantitative insights for optimizing brain-targeted antibody therapies and understanding pathological antibody distribution in CNS disorders.
抗体疗法在治疗中枢神经系统(CNS)疾病方面已显示出巨大潜力。由于治疗效果依赖于在特定脑区的充分暴露,因此对抗体在脑内分布的定量理解至关重要。此外,对抗体脑部分布的深入了解有助于阐明病理性抗体在脑炎期间是如何积累的。因此,本研究调查了非靶向结合抗体(曲妥珠单抗)和脑靶向结合抗体(抗NMDAR1)在大鼠全身给药和中枢神经系统内给药后的区域分布。全身给药后,两种抗体在脑区的分布相似,嗅球中的浓度显著更高。其他区域的暴露程度相当,纹状体或海马体的暴露程度最低。脑脊液内给药导致类似的分布模式,但浓度显著高于全身给药。相比之下,纹状体内给药导致分布各异,注射部位附近浓度最高。基于纹状体和间质液(ISF)浓度的计算表明,中枢神经系统内给药后抗体在血管周围间隙积聚。靶点结合主要在脑脊液内给药后影响分布,抗NMDAR1在此情况下早期ISF浓度较低,后期脑脊液浓度降低。这些发现为优化脑靶向抗体疗法以及理解中枢神经系统疾病中病理性抗体的分布提供了有价值的定量见解。